The short answer
NAD+ holds no marketing authorisation as a medicine from the MHRA, EMA or FDA. Some precursors are sold as food supplements in some jurisdictions, which is a different regulatory category with different rules, and neither position permits therapeutic claims.
Key facts
- MHRA medicine status
- Not authorised
- EMA medicine status
- Not authorised
- FDA drug status
- Not approved
- Precursors
- Food supplement status in some jurisdictions
- Supply basis here
- Laboratory research only
- Highest-risk framing
- Ageing and longevity language
The position
No regulator has authorised NAD+ as a medicine. Some precursors (nicotinamide riboside in particular) have food supplement status in certain jurisdictions, which permits sale but not therapeutic claims. Those are separate frameworks, and neither one covers NAD+ supplied as laboratory research material.
Why the supplement route confuses things
Because a compound sold legally in a shop looks approved. It is not. Food supplement frameworks assess safety for consumption; they do not assess efficacy for any purpose and do not permit claims that a product treats or prevents anything. A precursor's supplement status says nothing about NAD+, and nothing about efficacy.
Research material referenced
NAD+ 500mg, third-party HPLC tested
The claims problem specific to this category
The ageing literature is the most claim-prone body of work on this site. Its vocabulary (decline, restoration, reversal, longevity) reads as therapeutic before any claim is deliberately made, and it maps onto something everyone experiences. That combination makes the boundary easier to cross here than anywhere else in the catalogue.
Where the line sits
Reportable: that tissue NAD+ declines with age, that Covarrubias 2020 identified senescent-cell CD38 activity as a driver, that randomised trials of precursors have measured biomarker and physiological endpoints. Not sayable: that NAD+ slows ageing, restores energy, extends lifespan or affects any condition in any person.
The enforcement context
The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. The framework turns on the claim and intended use, not on the compound's chemistry. A non-peptide in a peptide catalogue is therefore regulated on the same basis as everything around it.
Frequently asked questions
Is NAD+ approved as a medicine?
No. It holds no marketing authorisation from the MHRA, EMA or FDA.
NR is sold in shops. Doesn't that mean it's approved?
No. Food supplement status assesses safety for consumption, not efficacy, and permits no therapeutic claims.
Why is this category particularly claim-prone?
The ageing literature's vocabulary reads as therapeutic before any claim is made, and it maps onto something universally experienced.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- Eighty Daltons Apart, and Metabolically OpposedNADP is NAD plus one phosphate - 743.4 against 663.4 Da. One drives catabolism, the other biosynthesis and antioxidant defence.
- Two Products in This Catalogue, One Connected SystemGlutathione reductase regenerates GSH from GSSG using NADPH. The antioxidant capacity of one molecule depends on the reduced pool of the other.
- Enzymes That Consume a Cofactor Rather Than Recycling ItSirtuins remove acetyl groups from proteins and consume NAD+ doing it. That consumption is what links them to the cell's metabolic state.
- DNA Damage Draws Down the PoolPoly(ADP-ribose) polymerases build chains from NAD+ in response to DNA damage. Extensive damage can deplete the pool substantially.
- The Clock Controls NAD, and NAD Feeds Back on the ClockA 2009 Science paper showed the circadian clock controls the NAD+ salvage pathway, while the NAD-consuming enzyme SIRT1 regulates the clock.